AiCure

R&D Trends

MD Anderson Moon Shots Program begins to generate innovations

Friday, October 31, 2014 02:07 PM

Improved surgical outcomes for ovarian cancer, expanded potential impact for new drugs and a novel family outreach program to head off cancers fueled by known genetic risk mutations are among the early innovations of the University of TexasMD Anderson Cancer Center's Moon Shots Program.

More... »


Merck discontinues tecemotide clinical program

Friday, October 31, 2014 02:03 PM

Merck will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in stage III non-small cell lung cancer (NSCLC).

More... »

CenterWatch

Report: Orphan drug market to reach $176B by 2020

Thursday, October 30, 2014 12:19 PM

In 2020 orphan drugs are expected to account for 19% of the total share of prescription drug sales excluding generics, reaching $176 billion in annual sales, according to the new EvaluatePharma Orphan Drug Report 2014 from London-based market intelligence firm Evaluate.

More... »

U.S. government institutes funding pause on gain-of-function research

Wednesday, October 29, 2014 01:39 PM

The U.S. government will undertake a deliberative process to assess the risks and benefits of certain gain-of-function (GOF) experiments with influenza, SARS and MERS viruses in order to develop a new federal policy regarding the funding of this research, announced Francis S. Collins, M.D., Ph.D., NIH director, in a statement. U.S. government agencies will institute a pause on the funding of any new studies involving these experiments.

More... »

NIH awards $5.9M in grants for frontotemporal degeneration research

Wednesday, October 29, 2014 01:34 PM

The NIH will award three large, five-year projects on a specific form of dementia, known as frontotemporal because of the areas of the brain that are affected. The projects, funded by the NIH's National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA) and the National Center for Advancing Translational Sciences (NCATS), will receive more than $5.9 million for 2014.

More... »

International GPCR Consortium formed with pharma, academia partners

Wednesday, October 29, 2014 01:32 PM

The generation of high-resolution pictures of hundreds of medically important proteins known as G-protein coupled receptors (GPCRs) will be the goal of a new international partnership. Called the GPCR Consortium, the nonprofit initiative brings together pharmaceutical companies and research institutes from three continents to advance GPCR research for drug development.

More... »

Bristol-Myers Squibb inks option to acquire F-star Alpha

Wednesday, October 29, 2014 01:30 PM

Bristol-Myers Squibb has entered into an agreement for the exclusive option to acquire F-star Alpha, an Austria-based biopharmaceutical company dedicated to developing novel bispecific antibody products, and gain worldwide rights to its lead asset FS102.

More... »

Qiagen, Astellas Pharma ink agreement to develop companion diagnostics

Wednesday, October 29, 2014 01:27 PM

Qiagen, a Netherlands-based provider of sample and assay technologies, has announced a master collaboration agreement with Astellas Pharma, an R&D-driven global pharmaceutical company headquartered in Japan, to develop and commercialize companion diagnostics paired with Astellas drugs for use in cancer and other diseases.

More... »

TFS, SCIderm partner for global dermatology trials

Wednesday, October 29, 2014 01:26 PM

TFS International (TFS) and SCIderm have entered into a strategic partnership agreement to combine resources and scientific expertise within dermatology development.

More... »

Cepheid, FIND, Rutgers collaborate on Xpert MTB/RIF test

Wednesday, October 29, 2014 01:22 PM

Cepheid, a Sunnyvale, Calif.-based molecular diagnostics company, FIND, a Switzerland-based international nonprofit organization and Rutgers New Jersey Medical School are collaborating to develop Xpert MTB/RIF Ultra, a next-generation test for Mycobacterium tuberculosis (TB) with increased sensitivity to aid in detection of patients with smear-negative TB, which often is associated with HIV co-infection. The collaboration also is receiving additional support from the National Institute of Allergy and Infectious Diseases at the NIH.

More... »

Link to survey
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs